Mr. Levitas has more than 25 years of experience as an antitrust lawyer addressing and resolving complex merger and conduct issues, particularly those affecting the healthcare, pharmaceutical, and technology sectors.

Mr. Levitas has served in a wide range of US government positions; most recently, he served for more than four years in the role of Deputy Director in the Bureau of Competition at the Federal Trade Commission (FTC) (2009-2013), where he was responsible for the Mergers 1, Health Care and Anticompetitive Practices divisions, as well as the FTC's Northeast Regional Office in New York.

Other experience includes nearly a decade as an antitrust counsel on Capitol Hill, including seven years as the Staff Director and Chief Counsel to the US Senate Judiciary Committee's Subcommittee on Antitrust, Competition Policy and Consumer Rights, and more than five years as a trial lawyer in the US Department of Justice Antitrust Division, where he was a member of the trial teams in the prosecution of several criminal price-fixing cases.

In private practice, Mr. Levitas provides counseling on the antitrust implications of day-to-day business practices and has represented FORTUNE 500 and other companies in transactions and in complex federal and state civil investigations and litigation focusing on antitrust and competition issues.


  • The National Titanium Dioxide Company Limited (d/b/a Cristal) in its estimated $2.4 billion sale of its titanium dioxide business to Tronox Limited, including the FTC's litigation challenging the transaction both in federal court and in FTC administrative proceedings.
  • Monsanto in connection with its $66 billion acquisition by Bayer.
  • AMC Entertainment Inc. in its $1.1 billion acquisition of Carmike Cinemas, creating the largest movie exhibitor in the US and world.
  • AT&T in connection with its $49 billion acquisition of DirecTV.
  • TriVascular Technologies, a medical device company, in its acquisition by Endologix.
  • AMC Entertainment Inc. in connection with DOJ's investigation of potential anticompetitive conduct by movie exhibitors.
  • Warby Parker, a leading Internet eyewear provider, in FTC Advanced Notice of Proposed Rulemaking regarding the Eyeglass Rule.
  • Hikma Pharmaceuticals in its $2 billion acquisition of the Roxane generic drug business and $300 million acquisition of generic injectable assets of Bedford Laboratories from a subsidiary of Boehringer Ingelheim.
  • Investment fund in evaluation of antitrust risk of various proposed transactions.
  • Major food services company as a third party in FTC investigation of proposed transaction.
  • Major patent holder as participant in FTC industry study of Patent Assertion Entities.


DOJ Changing Its Antitrust Approach to FRAND and SEPs (pdf)
Intellectual Property & Technology Law Journal, Volume 31, No. 4
FTC and Teva Reach Global Settlement of Reverse-Payment Charges
Wage-fixing and no-poach agreements
Federal Trade Commission Finds Trademark Settlement Agreement Search Ad Restrictions "Inherently Suspect" in 1-800 Contacts Decision (pdf)
IP Litigator, Volume 25, Number 1
Antitrust and Market Power—The Future of M&A
Moderator, Credit Suisse 4th Annual Washington Perspectives Conference, Washington, DC


The Legal 500 US
Antitrust: Merger Control (2015-2017)


  • JD, Harvard Law School, 1991, cum laude
  • BA, University of Pennsylvania, 1988, summa cum laude
  • District of Columbia
  • New York
Government and Military Service
  • Deputy Director, Bureau of Competition, Federal Trade Commission
  • Staff Director/Chief Counsel, Subcommittee on Antitrust, Competition Policy & Consumer Rights, US Senate Judiciary Committee
  • Trial Attorney, Antitrust Division, US Department of Justice
  • Special Assistant United States Attorney, US Attorney's Office, District of Columbia

Email Disclaimer